← 홈

Antibody · 위암

70개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-14 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 70개
AntibodyCHotRochederuxtecan plus fluoropyrim…Phase 2

trastuzumab (Herceptin, FLOT, 5-FU, leucovorin, docetaxel, oxaliplatin, 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab)

Adenocarcinoma of the Gastroesophageal Junction; Adenocarcinoma of the Stomach · Adenocarcinoma of the Gastroesophageal J

#AdenocarcinomaoftheGastroesophag#Antibody#Phase2#인기#항체+5
효능 ORR 61%임상시험 100상태 ACTIVE
AntibodyCPENG YUANPhase 2

QL1706 (Iparomlimab and Tuvonralimab, Iparomlimab and Tuvonralimab (QL1706))

Platinum Resistant Ovarian Cancer; Platinum Refractory Epithelial Ovarian Cancer · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#인기#항체+5
임상시험 97상태 RECRUITING
AntibodyCJunshi Biosciencesvedotin (EV) in combination…Phase 3

Toripalimab (Toripalimab)

Metastatic Colorectal Cancer; Liver Metastases · Gastric Cancer

#GastricCancer#Antibody#Phase3#인기#항체+5
임상시험 93상태 RECRUITING
AntibodyCEli Lilly and CompanyDeruxtecan]Phase 3

Ramucirumab (Ramucirumab)

Advanced Esophageal Adenocarcinoma; Advanced Gastric Adenocarcinoma · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase3#인기#항체+5
효능 ORR 40%임상시험 86상태 RECRUITING
AntibodyElevation OncologyDeruxtecan]Phase 1

CYRAMZA® (Ramucirumab, Ramucirumab (CYRAMZA®))

Stomach Neoplasm; Gastrointestinal Neoplasms · Stomach Neoplasm

#StomachNeoplasm#Antibody#Phase1#인기#항체+5
효능 ORR 44.7%임상시험 66상태 DISCONTINUED
AntibodyRochePhase 3

atezolizumab (Tecentriq, Atezolizumab + Bevacizumab)

Venous Thrombosis · Gastric Adenocarcinoma

#GastricAdenocarcinoma#Antibody#Phase3#인기#항체+5
효능 ORR 49.3%임상시험 63상태 RECRUITING
AntibodyGlaxoSmithKlinederuxtecan improved objecti…Phase 2

Dostarlimab (Dostarlimab)

Neoplasms · Stomach Neoplasm

#StomachNeoplasm#Antibody#Phase2#인기#항체+5
효능 ORR 88%임상시험 60상태 DISCONTINUED
AntibodystaleAstraZenecaPhase 3

Ramucirumab+ paclitaxel (Ramucirumab+ paclitaxel)

Gastric Cancer; Gastroesophageal Junction Cancer · Gastric Cancer

#GastricCancer#Antibody#Phase3#항체#면역항체+3
효능 ORR 58.2%임상시험 30상태 RECRUITING
AntibodystaleAstraZenecaPhase 3

zolbetuximab (zolbetuximab)

Gastric Cancer; Gastroesophageal Junction Adenocarcinoma · Locally Advanced Unresectable Gastroesop

#LocallyAdvancedUnresectableGastr#Antibody#Phase3#항체#면역항체+4
효능 ORR 48.1%임상시험 23상태 RECRUITING
AntibodystaleNeovii BiotechPhase 2

Catumaxomab (Catumaxomab)

Gastric Cancer; Gastric Adenocarcinoma · Gastric Cancer

#GastricCancer#Antibody#Phase2#항체#면역항체+3
임상시험 18상태 ACTIVE
AntibodyAstraZenecaPhase 1

durvalumab (Imfinzi, Administration of ceralasertib and durvalumab)

Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer · Adv Solid Malig - H&N SCC, ATM Pro / Def

#AdvSolidMalig-HNSCCATMProDef#Antibody#Phase1#항체#면역항체+5
효능 ORR 9.5%임상시험 12상태 RECRUITING
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab Injection [Opdivo])

Advanced Cancer; Gastric Cancer · Malignant Melanoma

#MalignantMelanoma#Antibody#Phase2#항체#면역항체+4
임상시험 7상태 RECRUITING
AntibodystaleGilead SciencesPhase 1

Andecaliximab (Andecaliximab)

Gastric Adenocarcinoma · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Phase1#항체#면역항체+3
효능 ORR 9.7%임상시험 3상태 DISCONTINUED
AntibodystaleAmgenPhase 2

Bemarituzumab (Bemarituzumab)

Adenocarcinoma · Gastric Cancer

#GastricCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 46.8%임상시험 2상태 ACTIVE
AntibodystaleRocheApproved

Oxaliplatin;Capecitabine;Bevacizumab (Oxaliplatin;Capecitabine;Bevacizumab)

Colorectal Cancer; Liver Metastases · Gastric Cancer

#GastricCancer#Antibody#Approved#항체#면역항체+4
임상시험 2상태 ACTIVE
AntibodystaleInnoventPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48 combined with Sintilimab and XELOX)

Gastric Cancer · Gastric Cancer

#GastricCancer#Antibody#Phase2#항체#면역항체+2
임상시험 2상태 ACTIVE
AntibodystaleMacroGenicsPhase 3

Tebotelimab (Tebotelimab)

Gastric Cancer; Gastroesophageal Junction Cancer · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase3#항체#면역항체+4
효능 ORR 62.5%임상시험 2상태 DISCONTINUED
AntibodyBiologicstaleShanghai Kechow Pharma, Inc.Phase 2

Tunlametinib+PD-1 mAb (Tunlametinib+PD-1 mAb)

Gastric Adenocarcinoma · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+3
임상시험 2상태 RECRUITING
AntibodyUniversity of Kansas Medical Ce…Phase 2

pembrolizumab (Keytruda, Adjuvant Treatment - mFOLFOX & Pembrolizumab)

Gastro Esophageal Junction Cancer; Stomach Cancer · Gastro Esophageal Junction Cancer

#GastroEsophagealJunctionCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleShanghai Zhongshan HospitalPhase 2

nivolumab (Opdivo, Anlotinib Hydrochloride With Nivolumab)

Gastric Adenocarcinoma; Esophageal Squamous Cell Carcinoma · Gastric Adenocarcinoma

#GastricAdenocarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE

1 / 4 페이지

← 이전다음 →